(Reuters) – Britain’s GSK and U.S.-based Vir Biotechnology will evaluate one of their monoclonal antibodies in patients with mild to moderate COVID-19 in an early- to mid-stage trial, the companies said on Tuesday.
The trial, under the UK-based AGILE initiative, is expected to begin in the first quarter of 2021 at multiple sites across the UK, the companies said in a joint statement.
(Reporting by Muvija M in Bengaluru; Editing by Saumyadeb Chakrabarty)
